The Association of Gross Tumor Volume and Its Radiomics Features with Brain Metastases Development in Patients with Radically Treated Stage III Non-Small Cell Lung Cancer
Authors:
- Haiyan ZengHZHaiyan Zeng
- Fariba TohidinezhadFariba Tohidinezhad
- Dirk K. M. De RuysscherDirk K. M. De Ruysscher
- Yves C. P. WillemsYWYves C. P. Willems
- Juliette H. R. J. DegensJDJuliette H. R. J. Degens
- Vivian E. M. van Kampen-Van Den BoogaartVBVivian E. M. van Kampen-Van Den Boogaart
- Cordula PitzCPCordula Pitz
- Francesco CortiulaFCFrancesco Cortiula
- Lloyd BrandtsLBLloyd Brandts
- Lizza E. L. HendriksLHLizza E. L. Hendriks
- Alberto TraversoATAlberto Traverso
Open Access
Abstract
Purpose: To identify clinical risk factors, including gross tumor volume (GTV) and radiomics features, for developing brain metastases (BM) in patients with radically treated stage III non-small cell lung cancer (NSCLC). Methods: Clinical data and planning CT scans for thoracic radiotherapy were retrieved from patients with radically treated stage III NSCLC. Radiomics features were extracted from the GTV, primary lung tumor (GTVp), and involved lymph nodes (GTVn), separately. Competing risk analysis was used to develop models (clinical, radiomics, and combined model). LASSO regression was performed to select radiomics features and train models. Area under the receiver operating characteristic curves (AUC-ROC) and calibration were performed to assess the models’ performance. Results: Three-hundred-ten patients were eligible and 52 (16.8%) developed BM. Three clinical variables (age, NSCLC subtype, and GTVn) and five radiomics features from each radiomics model were significantly associated with BM. Radiomic features measuring tumor heterogeneity were the most relevant. The AUCs and calibration curves of the models showed that the GTVn radiomics model had the best performance (AUC: 0.74; 95% CI: 0.71–0.86; sensitivity: 84%; specificity: 61%; positive predictive value [PPV]: 29%; negative predictive value [NPV]: 95%; accuracy: 65%). Conclusion: Age, NSCLC subtype, and GTVn were significant risk factors for BM. GTVn radiomics features provided higher predictive value than GTVp and GTV for BM development. GTVp and GTVn should be separated in clinical and research practice.Keywords
Funding Information
- China Scholarship Council (CSC 201909370087)
This publication has 37 references indexed in Scilit:
- Risk Factors for Brain Metastases in Locally Advanced Non-Small Cell Lung Cancer With Definitive Chest RadiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- A Systematic Review of Risk Factors for Brain Metastases and Value of Prophylactic Cranial Irradiation in Non-Small Cell Lung CancerAsian Pacific Journal of Cancer Prevention, 2014
- GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: Subgroup analysis of the prospective randomized CHARTWEL trialRadiotherapy and Oncology, 2013
- Development and Validation of a Prognostic Model Using Blood Biomarker Information for Prediction of Survival of Non–Small-Cell Lung Cancer Patients Treated With Combined Chemotherapy and Radiation or Radiotherapy Alone (NCT00181519, NCT00573040, and NCT00572325)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Development and External Validation of Prognostic Model for 2-Year Survival of Non–Small-Cell Lung Cancer Patients Treated With ChemoradiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- Understanding sensitivity and specificity with the right side of the brainBMJ, 2003
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889